drugset / Trial / NCT01046253
Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study
RandomizedCrossoverOpen-label
Summary
The object of this study is to compare the relative bioavailability of lansoprazole 30 mg delayed-release capsules (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of PREVACID® capsules (TAP Pharmaceuticals, Inc.) in healthy, adult, subjects under fasting conditions with dosing by applesauce-sprinkle method.
Timeline
- Start
- 2004-01
- Primary completion
- 2004-01
- Completion
- 2004-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lansoprazole | Other / unclassified | 30 mg | — |
Indications
No indication recorded.